Fulltext

Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma

Chow PK 1 , Poon DY 2 , Khin MW 3 , Singh H 4 , Han HS 5 , Goh AS 6 Show all authors , Choo SP 2 , Lai HK 6 , Lo RH 6 , Tay KH 6 , Lim TG 6 , Gandhi M 7 , Tan SB 7 , Soo KC 1 , Asia-Pacific Hepatocellular Carcinoma Trials Group

Affiliations 

  • 1 National Cancer Centre, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore; Duke-NUS Graduate Medical School, Singapore, Singapore
  • 2 Singapore General Hospital, Singapore, Singapore
  • 3 Yangon Gastrointestinal and Liver Centre, Yangon, Myanmar
  • 4 Selayang Hospital, Selangor, Malaysia
  • 5 Seoul National University Bundang Hospital, Bundang, South Korea
  • 6 National Cancer Centre, Singapore, Singapore
  • 7 Duke-NUS Graduate Medical School, Singapore, Singapore; Singapore Clinical Research Institute, Singapore, Singapore
PLoS One, 2014;9(3):e90909.
PMID: 24614178 DOI: 10.1371/journal.pone.0090909

Abstract

The safety and tolerability of sequential radioembolization-sorafenib therapy is unknown. An open-label, single arm, investigator-initiated Phase II study (NCT0071279) was conducted at four Asia-Pacific centers to evaluate the safety and efficacy of sequential radioembolization-sorafenib in patients with hepatocellular carcinoma (HCC) not amenable to curative therapies.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications